Abstract

Mycobacterium tuberculosis is an important global pathogen for which new drugs are urgently required. The ability of the organism to survive and multiply within macrophages may contribute to the lengthy treatment regimen with multiple drugs that are required to cure the infection. We screened the MyriaScreen II diversity library of 10,000 compounds to identify novel inhibitors of M. tuberculosis growth within macrophage-like cells using high content analysis. Hits were selected which inhibited the intramacrophage growth of M. tuberculosis without significant cytotoxicity to infected macrophages. We selected and prioritized compound series based on their biological and physicochemical properties and the novelty of the chemotypes. We identified five chemical classes of interest and conducted limited catalog structure-activity relationship studies to determine their tractability. We tested activity against intracellular and extracellular M. tuberculosis, as well as cytoxicity against murine RAW264.7 and human HepG2 cells. Benzene amide ethers, thiophene carboxamides and thienopyridines were only active against intracellular bacteria, whereas the phenylthiourea series was also active against extracellular bacteria. One member of a phenyl pyrazole series was moderately active against extracellular bacteria. We identified the benzene amide ethers as an interesting series for further work. These new compound classes serve as starting points for the development of novel drugs to target intracellular M. tuberculosis.

Highlights

  • Tuberculosis (TB) is the leading cause of death from a bacterial infection worldwide

  • RAW264.7 cells were infected with M. tuberculosis DsRed from plasmid pBlazeC8 (DREAM8) as described (Manning et al, 2017) at an MOI of 1 for 24 h and extracellular bacteria removed by washing

  • We were interested in identifying new anti-tubercular molecules with activity against intracellular bacteria

Read more

Summary

Introduction

Tuberculosis (TB) is the leading cause of death from a bacterial infection worldwide. Despite the availability of chemotherapy, TB is responsible for >10 million infections annually and >1 million deaths (Gordon and Parish, 2018; Global Tuberculosis Report, 2020). The increasing incidence of drug failure for TB due to widespread drug-resistant infections underscores the urgent need for new drugs and new bacterial targets for M. tuberculosis. The physiology and metabolism of M. tuberculosis within macrophages is very different from extracellular bacteria and so the complement of essential genes differs (Sassetti et al, 2001; Sassetti et al, 2003; Sassetti and Rubin, 2003). From a drug discovery perspective, this means that intracellular bacteria have additional essential processes that can be targeted by chemical inhibition (Manjunatha and Smith, 2015; Parish, 2019; Parish, 2020)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call